July 2016

GRC NPC – Tsao, George SH

George Tsao (University of Hong Kong, Hong Kong SAR China)”Establishment of New NPC Xenografts and Cell Lines for EBV Studies”  曹世華 Int J Cancer Vol 83 1999 Lim (C-6661) elaborate on NPC-HeLa hybrid contamination available NPC cell lines (refers to KW Lo’s paper and JV Strong RNA-seq paper) Surgical Maxi William NPC Xeno43 65M recurrent […]

GRC NPC – Tsao, George SH Read More »

GRC NPC – Ma, J and Bei, JX

2018 GRC NPC Jun Ma (Sun Yat-Sen Medical University, China)“Comprehensive Treatment Strategy in Locoregionally Advanced Nasopharyngeal Carcinoma” Evolving National Comprehensive Cancer Network’s (NCCN) guidelines (2018) of the nasopharynx Lancet Oncol. 2016 Nov;17(11):1509-1520.  Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Sun Y1,

GRC NPC – Ma, J and Bei, JX Read More »

GRC NPC – Longnecker, R

Richard Longnecker (Northwestern University, USA)“EBV Entry into Host” Lindsey Hutt-Fletcher retires last year. Give all the reagents to Longnecker.Cell-cell fusiongp42 and MHC II structure.Soluble gb42 stimulates fusion with B cells but inhibits fusion with epithelials. From Ming-HanLongnecker: EBV entrygp350 gHgL gB BMRF2gB( gp110) is highly conserved in HerpesvirusgHgL against avb6)gHgL+gp42: against MHCII   3D structure(Mbio

GRC NPC – Longnecker, R Read More »

GRC NPC – Lo, Yuk-Ming Dennis

2016 GRC NPC Dennis Lo (Chinese University of Hong Kong, Hong Kong SAR China)  “Plasma DNA Analysis for Detecting NPC: Biological Insights and Clinical Applications” 盧煜明 (Wiki https://goo.gl/HTNGFn) 香港中文大學網站 https://goo.gl/03EPTe    http://goo.gl/i7PNRf ) Size based molecular diagnosis (difference between maternal and fetal , because the fetal DNA has no linker, therefore is 10 bp shorter)

GRC NPC – Lo, Yuk-Ming Dennis Read More »

GRC NPC – Fuchs, Elaine

Elaine Fuchs (The Rockefeller University, USA HHMI Investigator) “Transition of Normal Epithelia to Cancer”Webpage http://www.rockefeller.edu/research/faculty/labheads/ElaineFuchs/#content a student of Howard Green, who just passed away several mo ago The foundation of embryonic stem cell culture to come in 1980s burn therapy quiescent stem cell and primed stem cells awaiting for activation Hair follicle stem cells BMP signaling

GRC NPC – Fuchs, Elaine Read More »

GRC NPC – Clevers, H

Hans Clevers (Hubrecht Institute, The Netherlands)“Wnt Signaling and Cancer” The champion of all stem cells : crypt base paneth cells Wnt is required to maintain crypt stem cells in colon cancer,Wnt is locked in On state。 Lqr5 is an unusual component that marks stem cells in the crypts。 15 stem cell to begin  (mixed with1

GRC NPC – Clevers, H Read More »

GRC NPC – Lo, KW

2018 GRC NPC [NPC tumorigenesis model] WES-seq of 111 NPC patient Nat Commun 18: 14121, 2017 LCM enrichment of tumor cells. -> higher somatic mutation than the Singapore study (because of LCM?) LMP1 activates both canonical and non-canonical NFKB pathways Homozygous deletion f BIRC2(cIAP) and BIRC3(cIAP2) in primary NPC Identification of a novel 12p13.3 amplicon

GRC NPC – Lo, KW Read More »

GRC NPC – Liu, Fei-Fei

Fei-Fei Liu (Princess Margaret Hospital, Canada)“Prognostic Significance of miRNA Signatures for Detection of Metastatic NPC” metastatic NPC, metastamirs   let-7  miR9 Nanostring 654 miRNA + 34 EBV mi RNA +   mi RNA from other viruses on 124 patients Bruce Oncotarget , 2015 miRNAS 154 + miRNA 449 – MENA 140 – MIRNA 34c (Bruce

GRC NPC – Liu, Fei-Fei Read More »

GRC NPC – Lu, Xin

Xin Lu (Ludwig Institute for Cancer Research, United Kingdom) “p53, a Key Regulator of Genomic Stability in Cancer” Discovery of p53: 1979 about the same time “tumor antigen” by Lloyd and Old, PNAS. Binding partner of large T antigen of SV40 (A Larid and David Lane) p53 mutation in 30–40% BL, why only 9 % in

GRC NPC – Lu, Xin Read More »

GRC NPC – Futreal, Andrew

Andrew Futreal (University of Texas MD Anderson Cancer Center, USA) “Cancer Genomics and Evolution” tumors heterogeneous from one patient to another intratumor heterogeneity—a state where subclonal subpopulations within the same tumor accumulate different kinds of mutations over time (65% heterogeneity in RCC) 1 mutation/wk, 40 mutations / year APOLLO platform  https://goo.gl/uRmjHX Moon shot platform 40% subclonal

GRC NPC – Futreal, Andrew Read More »

Scroll to Top